Context Therapeutics reports 2023 EPS ($1.50) vs. (93c) last year

“During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 (“CLDN6″) x CD3 bispecific antibody, toward a first-in-human clinical study. Preclinical data presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting highlighted the broad therapeutic potential of CTIM-76 when targeting CLDN6-positive tumors. The preclinical data further support CTIM-76’s differentiated product profile, including its potential to address limitations of first-generation CLDN6-targeted clinical-stage therapies,” said Martin Lehr, CEO of Context. “We look forward to filing an Investigational New Drug Application with the U.S. Food and Drug Administration by the end of March 2024 for CTIM-76. We then plan to initiate a Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers upon receiving IND clearance from the FDA.”